CD163 and B-cell chronic lymphocytic leukemia: We further enriched the analysis with several myeloid markers to better distinguish potential differences between NLC from PBMC with low CLL cells in vitro viability (noted: low viability) and from PBMC with high CLL cells in vitro viability (noted: high viability), In comparison to isotypic controls, expression of CD163, CD206, CD169, CD209, and CD14 was higher for NLC from samples with high viability (Figure 1D: green) compared to expression by NLC from samples with low viability (Figure 1D: red).